Introduction: Introduction: Shigellosis is an intestinal infection caused by Shigella bacteria. Globally, shigellosis occurs in at least 80 million people and kills about 700,000 people annually. In severe cases, antibiotics may be used, but resistance is common. Ciprofloxacin and azithromycin are commonly used to treatment of the disease.
Methods: Method: A Systematic Review of the current published literature on Shigella sonnei resistance gene to azithromycin was performed according to the preferred report items for systematic review.
Results: Results: Azithromycin is one type of acid stable orally administered macrolide used to treat a number of bacterial infections. Azithromycin is increasingly used to treat shigellosis despite the lack of interpretive guidelines and limited clinical evidence. The present study determined the susceptibility of azithromycin and linked it to macrolide-resistant genes in Shigella spp. Our study shows that DSA was severe for Shigella sonnei isolates and that the mphA gene was collected by plasmid, the most common macrolide resistance gene detected in Shigella isolates.
Conclusion: Conclusion: Monitoring of Shigella susceptibility and studying the mechanism of Shigella resistance to azithromycin, due to the limited choice of treatment for shigellosis, are essential. The azithromycin treatment failures demonstrate the importance of clinical points in assisting physicians in identifying alternative treatment options for resistant strains. In addition, these therapeutic failures highlight the need for comprehensive sensitivity testing and systematic results, especially given the emergence of drug-resistant Shigella among a wide range of patient populations.
Keywords: Keywords: Shigella sonnei, Azithromycin, Drug resistance, Resistance gene